The American Cancer Society (ACS) has issued updated guidelines recommending more frequent prostate cancer screening for men, marking a significant shift from its 2010 recommendations. The new guidance, released on November 12, advises men aged 50 to 69 with average risk to undergo prostate-specific antigen (PSA) testing every two years, while high-risk groups—including Black men and those with a family history of prostate cancer—should begin annual screenings at age 45.
The ACS previously recommended in 2010 that men at average risk consult with their healthcare providers about PSA testing rather than establishing a routine schedule. The updated guidelines reflect new evidence suggesting that regular PSA testing significantly reduces prostate cancer mortality and the diagnosis of advanced-stage disease.
Key changes in the new guidelines:
- Average-risk men (50–69): PSA test every two years.
- High-risk men (Black men, family history): PSA test annually, starting at age 45.
- Men over 70: Individualized screening decisions based on health status.
The ACS cited a 2025 European study in men aged 55–69, which found that PSA testing lowered prostate cancer deaths by 13% compared to no screening. The organization also emphasized advances in diagnostic methods, such as repeating PSA tests to confirm elevated levels and using MRI scans to reduce unnecessary biopsies.
Dr. Robert Smith, senior vice president for early cancer detection science at the ACS, stated: “These updated guidelines are a critical step toward preventing diagnoses of advanced disease, reducing premature deaths, and minimizing treatment-related harms.” He added that the changes aim to reduce prostate cancer disparities, noting that Black men experience a 67% higher incidence and nearly double the mortality rate compared to White men.
Dr. William Dahut, chief scientific officer at the ACS, highlighted the urgency of addressing inequities, saying: “Our aim is also to help reduce prostate cancer disparities and ease the disease burden.”
The updated guidance follows a rise in advanced prostate cancer cases nationwide, prompting calls for earlier and more aggressive screening. Former President Joe Biden, who has publicly discussed his prostate cancer diagnosis, endorsed the new recommendations in a post on X, urging men to get screened and consult their doctors.
How PSA testing works:
PSA tests measure levels of prostate-specific antigen, a protein produced by both healthy and cancerous prostate cells. Elevated PSA levels do not always indicate cancer—they may also result from benign conditions like an enlarged prostate or temporary spikes from vigorous exercise. The ACS advises confirmatory testing to avoid unnecessary follow-up procedures.
Balancing benefits and risks:
While PSA testing has been credited with earlier cancer detection, widespread screening in the past led to overtreatment of slow-growing tumors and unnecessary biopsies. The updated guidelines emphasize more targeted screening to catch lethal tumors early while minimizing harm from overdiagnosis.
Men considering screening are encouraged to discuss risks, benefits, and personal risk factors with their healthcare providers to make informed decisions.